DLL4 and asthma: Previous studies have reported that blocking Dll-4-Notch signaling in animal models of experimental autoimmune encephalomyelitis and asthma decreased both Th17 response and clinical symptoms severity (Weng et al., 2017; Bassil et al., 2011).